查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1649467

皮下給藥市場：預測（2025-2030）

Subcutaneous Drug Delivery Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 145 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

皮下給藥市場規模在 2025 年預計為 417.04 億美元，預計到 2030 年將達到 565.03 億美元，預測期內的複合年成長率為 6.26%。

皮下給藥裝置市場正在經歷快速成長，主要受對先進微創解決方案的需求不斷成長的推動。心血管疾病（CVD）和糖尿病等慢性疾病的發生率不斷上升，加上生物藥品開發的進步，正在改變醫療保健模式。

皮下給藥市場促進因素：

  • 藥物設備系統在慢性病管理中的作用：氣喘、多發性硬化症、心血管疾病和糖尿病等慢性病的管理是全球面臨的重大健康挑戰。例如，美國氣喘和過敏基金會報告稱，氣喘影響著美國約 2800 萬人，即大約每 12 人中就有 1 人。預填充式注射器和自動注射器等藥物裝置輸送系統的採用是改善病患治療效果和減輕醫療負擔的重大進步。這些系統透過提供精確的劑量增加了患者的便利性，從而減少了因臨床程序而去醫院就診的需要並解決了慢性病管理中的關鍵差距。

糖尿病患者數量的不斷增加促使企業進行創新並採取策略性舉措，引進先進的皮下給藥裝置。預填充式注射器，尤其是胰島素自動注射器，已成為一種創新的解決方案，使患者能夠以最小的不適感有效地自行給藥。根據IDF糖尿病地圖集（2021年），20-79歲的成年人中有10.5％患有糖尿病，近一半的人並未意識到自己的症狀。預測表明，到 2045 年，每八名成年人中就有一人患有糖尿病，人數將增加 46%，達到 7.83 億。其中超過 90% 的病例為第 2 型糖尿病，社會經濟、人口、環境和遺傳因素都是導致此疾病的因素。

皮下給藥市場的地理展望：

  • 預計北美將佔據主要市場佔有率：預計在預測期內北美將主導皮下藥物輸送裝置市場。這一成長得益於發達的醫療保健基礎設施、對創新的重視以及先進的技術力。北美醫療保健產業受益於高度發展的醫療設施和廣泛使用的先進藥物傳輸技術。

此外，對本地研發的大量投資正在推動設備的持續創新。糖尿病、自體免疫疾病和心血管疾病等慢性病的高盛行率是北美市場的主要驅動力。根據美國美國有約2,970萬人（約佔總人口的8.9%）患有糖尿病。用於皮下給藥的設備，例如胰島素筆、自動注射器和穿戴式注射器，正在成為慢性病的重要管理工具。這些設備為需要持續照護的患者提供了更大的便利性、準確性和易用性。摘要，皮下給藥市場預計將出現顯著成長，這歸因於一些因素，這些因素強化了這一不斷擴大的市場格局，例如對慢性病管理創新解決方案的需求不斷成長、糖尿病和心血管疾病等疾病的患病率不斷上升、藥物設備技術的進步、支持性法規環境、以及重大的地理發展，尤其是在北美。

為什麼要購買這份報告？

  • 深刻分析：獲得深入的市場洞察，涵蓋主要和新興地區，重點關注客戶群、政府政策和社會經濟因素、消費者偏好、垂直行業和其他子區隔。
  • 競爭格局：了解全球主要企業所採用的策略策略，並了解正確策略帶來的潛在市場滲透率。
  • 市場趨勢和促進因素：探索動態因素和關鍵市場趨勢以及它們將如何影響未來的市場發展。
  • 可行的建議：利用洞察力做出策略決策，在動態環境中開闢新的業務流和收益。
  • 適合廣泛的用戶：對於新興企業、研究機構、顧問公司、中小企業和大型企業來說，它都是實用且具有成本效益的。

它有什麼用途？

產業與市場分析、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本支出決策、法律規範與影響、新產品開發、競爭影響

研究範圍

  • 2022 年至 2030 年的實際資料和預測
  • 成長機會、挑戰、供應鏈前景、法規結構、顧客行為、趨勢分析
  • 競爭定位、策略與市場佔有率分析
  • 收益成長和預測包括國家在內的細分市場和地區分析
  • 公司概況（策略、產品、財務、主要發展等）

皮下給藥市場細分如下：

依產品類型：

  • 預填充式注射器
  • 筆型注射器
  • 自動注射器
  • 穿戴式注射器
  • 無針注射器

按用途分類：

  • 糖尿病
  • 生育能力
  • 腫瘤學
  • 其他

按最終用戶

  • 醫院和診所
  • 居家醫療
  • 門診手術中心

按地區：

  • 北美洲
  • 美國
  • 加拿大
  • 墨西哥
  • 南美洲
  • 巴西
  • 阿根廷
  • 其他
  • 歐洲
  • 英國
  • 德國
  • 法國
  • 義大利
  • 其他
  • 中東和非洲
  • 沙烏地阿拉伯
  • 以色列
  • 其他
  • 亞太地區
  • 日本
  • 中國
  • 印度
  • 韓國
  • 印尼
  • 泰國
  • 其他

目錄

第 1 章 簡介

  • 市場概況
  • 市場定義
  • 研究範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關人員的主要利益

第2章調查方法

  • 研究設計
  • 研究過程

第3章執行摘要

  • 主要發現
  • 分析師觀點

第4章 市場動態

  • 市場促進因素
  • 市場限制
  • 波特五力分析
  • 產業價值鏈分析

5. 皮下給藥市場（依產品類型）

  • 介紹
  • 預填充式注射器
  • 筆型注射器
  • 自動注射器
  • 穿戴式注射器
  • 無針注射器

第6章 皮下給藥市場（依應用）

  • 介紹
  • 糖尿病
  • 生育能力
  • 腫瘤學
  • 其他

7. 皮下給藥市場（依最終用戶分類）

  • 介紹
  • 醫院和診所
  • 居家醫療
  • 門診手術中心

8. 皮下給藥市場（按地區）

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 其他
  • 中東和非洲
    • 沙烏地阿拉伯
    • 以色列
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 印尼
    • 泰國
    • 其他

第9章競爭格局及分析

  • 主要企業和策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 競爭儀錶板

第10章 公司簡介

  • Gerresheimer AG
  • Ypsomed AG
  • Medtronic Plc
  • Sanofi
  • Novo Nordisk
  • Becton, Dickinson and Company
  • Elcam Medical Group
  • Unilife Corporation
  • Insulet Corporation
  • Eli Lilly and Company
簡介目錄
Product Code: KSI061617243

The subcutaneous drug delivery market is estimated at USD41.704 billion in 2025 and is anticipated to grow at a CAGR of 6.26% during the forecast period and reach USD56.503 billion in 2030.

The market for subcutaneous drug delivery devices is experiencing rapid growth, primarily fueled by the increasing demand for advanced minimally invasive solutions. The rising prevalence of chronic conditions such as cardiovascular disease (CVD) and diabetes, along with advancements in biological drug development, is transforming the healthcare landscape.

Drivers of the Subcutaneous Drug Delivery Market:

  • Role of Drug-Device Systems in Chronic Disease Management: The management of chronic diseases such as asthma, multiple sclerosis, cardiovascular conditions, and diabetes presents significant global health challenges. For example, the Asthma and Allergy Foundation of America reports that asthma affects nearly 28 million people in the United States, or about 1 in 12 individuals. The adoption of drug-device delivery systems, including prefilled syringes and autoinjectors, represents a significant advancement in improving patient outcomes and reducing healthcare burdens. These systems enhance patient convenience by delivering accurate doses, thereby decreasing the need for hospital visits for clinical procedures and addressing critical gaps in chronic disease management.

The increasing diabetes patient population has prompted companies to innovate and implement strategic initiatives to introduce advanced subcutaneous drug delivery devices. Prefilled syringes, particularly insulin autoinjectors, have emerged as transformative solutions that allow patients to self-administer medications efficiently and with minimal discomfort. According to the IDF Diabetes Atlas (2021), 10.5% of adults aged 20 to 79 years have diabetes, with nearly half unaware of their condition. Projections indicate that by 2045, 1 in 8 adults will be living with diabetes, marking a 46% increase to an estimated 783 million individuals. Over 90% of these cases are type 2 diabetes, driven by socio-economic, demographic, environmental, and genetic factors.

Geographical Outlook of the Subcutaneous Drug Delivery Market:

  • North America Expected to Hold a Major Market Share: North America is anticipated to dominate the subcutaneous drug delivery devices market during the forecast period. This growth is attributed to a well-developed healthcare infrastructure, a strong emphasis on innovation, and advanced technological capabilities within the region. The healthcare sector in North America benefits from highly developed medical facilities that provide widespread access to advanced drug delivery technologies.

Additionally, significant investments in regional research and development are driving continuous innovation in subcutaneous drug delivery devices. The high prevalence of chronic conditions such as diabetes, autoimmune disorders, and cardiovascular diseases serves as a primary market driver in North America. According to estimates from the Centers for Disease Control and Prevention (CDC), approximately 29.7 million people in the United States-about 8.9% of the population-had diabetes in 2022. This underscores the importance of effective and accessible treatment options.Devices designed for subcutaneous drug delivery-such as insulin pens, auto-injectors, and wearable injectors-are becoming essential management tools for chronic conditions. These devices offer greater convenience, precision, and user-friendliness for patients requiring ongoing treatments. With an aging population and an increasing prevalence of chronic diseases, the market for these devices is expected to expand further, solidifying North America's position as a leader in the global subcutaneous drug delivery market.In summary, the subcutaneous drug delivery market is poised for substantial growth driven by rising demand for innovative solutions in chronic disease management, increasing prevalence of conditions like diabetes and cardiovascular diseases, advancements in drug-device technology, supportive regulatory environments, and significant geographical developments-particularly within North America-that enhance this expanding market landscape.

Reasons for buying this report:-

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub- segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape up future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data & forecasts from 2022 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

Subcutaneous Drug Delivery Market has been segmented as following:

By Product Type:

  • Prefilled syringes
  • Pen injector
  • Autoinjectors
  • Wearable injectors
  • Needle-free Injectors

By Application:

  • Diabetes
  • Fertility
  • Oncology
  • Others

By End-Users:

  • Hospitals and Clinics
  • Homecare Settings
  • Ambulatory Surgical Centers

By Geography:

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • UK
  • Germany
  • France
  • Italy
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits for the Stakeholders

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Process

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. Analyst View

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Supplier
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. The Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. SUBCUTANEOUS DRUG DELIVERY MARKET BY PRODUCT TYPE

  • 5.1. Introduction
  • 5.2. Prefilled syringes
  • 5.3. Pen injector
  • 5.4. Autoinjectors
  • 5.5. Wearable injectors
  • 5.6. Needle-free Injectors

6. SUBCUTANEOUS DRUG DELIVERY MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Diabetes
  • 6.3. Fertility
  • 6.4. Oncology
  • 6.5. Others

7. SUBCUTANEOUS DRUG DELIVERY MARKET BY END-USERS

  • 7.1. Introduction
  • 7.2. Hospitals and Clinics
  • 7.3. Homecare Settings
  • 7.4. Ambulatory Surgical Centers

8. SUBCUTANEOUS DRUG DELIVERY MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. USA
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. UK
    • 8.4.2. Germany
    • 8.4.3. France
    • 8.4.4. Italy
    • 8.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. Israel
    • 8.5.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Gerresheimer AG
  • 10.2. Ypsomed AG
  • 10.3. Medtronic Plc
  • 10.4. Sanofi
  • 10.5. Novo Nordisk
  • 10.6. Becton, Dickinson and Company
  • 10.7. Elcam Medical Group
  • 10.8. Unilife Corporation
  • 10.9. Insulet Corporation
  • 10.10. Eli Lilly and Company